Carla De Giovanni
Carla De Giovanni
Professor Oncology, University Bologna
Verified email at
TitleCited byYear
Interleukin 12–mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice
K Boggio, G Nicoletti, E Di Carlo, F Cavallo, L Landuzzi, C Melani, ...
Journal of Experimental Medicine 188 (3), 589-596, 1998
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
P Nanni, G Nicoletti, C De Giovanni, L Landuzzi, E Di Carlo, F Cavallo, ...
Journal of Experimental Medicine 194 (9), 1195-1206, 2001
2011: the immune hallmarks of cancer
F Cavallo, C De Giovanni, P Nanni, G Forni, PL Lollini
Cancer Immunology, Immunotherapy 60 (3), 319-326, 2011
TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma
P Nanni, C De Giovanni, PL Lollini, G Nicoletti, G Prodi
Clinical & experimental metastasis 1 (4), 373-380, 1983
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice
E Quaglino, M Iezzi, C Mastini, A Amici, F Pericle, E Di Carlo, SM Pupa, ...
Cancer research 64 (8), 2858-2864, 2004
DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis
FA Scholl, P McLoughlin, E Ehler, C De Giovanni, BW Schäfer
The Journal of cell biology 151 (3), 495-506, 2000
Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas.
R Ferracini, M Olivero, MFR Di, M Martano, CG De, P Nanni, G Basso, ...
Oncogene 12 (8), 1697-1705, 1996
Expression of an IGF‐I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells
K Scotlandi, S Avnet, S Benini, MC Manara, M Serra, V Cerisano, ...
International journal of cancer 101 (1), 11-16, 2002
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent
P Nanni, L Landuzzi, G Nicoletti, C De Giovanni, I Rossi, S Croci, A Astolfi, ...
The Journal of Immunology 173 (4), 2288-2296, 2004
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
C De Giovanni, G Nicoletti, L Landuzzi, A Astolfi, S Croci, A Comes, ...
Cancer research 64 (11), 4001-4009, 2004
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells
S Croci, L Landuzzi, A Astolfi, G Nicoletti, A Rosolen, F Sartori, MY Follo, ...
Cancer research 64 (5), 1730-1736, 2004
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
E Quaglino, S Rolla, M Iezzi, M Spadaro, P Musiani, C De Giovanni, ...
The Journal of clinical investigation 113 (5), 709-717, 2004
Inhibition of tumor growth and enhancement of metastasis after transfection of the γ‐interferon gene
PL Lollini, MC Bosco, F Cavallo, C De Giovanni, M Giovarelli, L Landuzzi, ...
International journal of cancer 55 (2), 320-329, 1993
Molecular and cellular biology of rhabdomyosarcoma
C De Giovanni, L Landuzzi, G Nicoletti, PL Lollini, P Nanni
Future Oncology 5 (9), 1449-1475, 2009
The occurrence of multiple steroid hormone receptors in disease‐free and neoplastic human ovary
MC Galli, C De Giovanni, G Nicoletti, S Grilli, P Nanni, G Prodi, G Gola, ...
Cancer 47 (6), 1297-1302, 1981
The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit
L Landuzzi, C De Giovanni, G Nicoletti, I Rossi, C Ricci, A Astolfi, ...
The American journal of pathology 157 (6), 2123-2131, 2000
p185neu protein is required for tumor and anchorage‐independent growth, not for cell proliferation of transgenic mammary carcinoma
P Nanni, SM Pupa, G Nicoletti, C De Giovanni, L Landuzzi, I Rossi, ...
International journal of cancer 87 (2), 186-194, 2000
Establishment and characterization of multidrug-resistant human osteosarcoma cell lines.
M Serra, K Scotlandi, MC Manara, D Maurici, PL Lollini, CG De, G Toffoli, ...
Anticancer research 13 (2), 323-329, 1993
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice
JSD Cruz, SY Lau, EM Ramirez, C De Giovanni, G Forni, SL Morrison, ...
Vaccine 21 (13-14), 1317-1326, 2003
A mutation threshold distinguishes the antitumorigenic effects of the mitochondrial gene MTND1, an oncojanus function
G Gasparre, I Kurelac, M Capristo, L Iommarini, A Ghelli, C Ceccarelli, ...
Cancer research 71 (19), 6220-6229, 2011
The system can't perform the operation now. Try again later.
Articles 1–20